Cellectricon AB

Cellectricon captures the emerging paradigm shift in drug discovery towards microfluidic assays and the products are designed to enable substantial productivity increases with maximized efficiency, data quality, throughput and analytical precision. Cellectricon's unique approach of combining microfluidics engineering with biology has enabled the development of completely new types of miniaturized real time cell-based screening devices for applications in biotechnology, biomedical research and drug discovery.

The company has successfully launched two products up to date with strong customer validation. Ten out of twelve big pharma companies has already adopted the first product the Dynaflow® System for ion channel drug discovery. In December 2005 the company launched their second product line, Cellaxess™ , highly-efficient & easy-to-use electroporation systems for transfection of adherent cells.